05 okt: Indkaldelse til ordinær generalforsamling
05 okt: Forløb af generalforsamling
05-10-2017 19:27:15

Grant of Restricted Stock Units and Warrants to Genmab employees

Relateret indhold
22 nov - 
Onsdagens aktier: Kapitalfonds retræte trak Pandora til..
22 nov - 
Aktier/middag: GN, Vestas og Pandora i kamp om topplads..
22 nov - 
Aktier/åbning: Beherskede udsving i C20 og lidt revanch..
Relateret debat
23 nov - 
Hvordan med dine Vestas? Er det minus 25%, du købte jo ..
22 nov - 
Lego .. da du ikke kender min baggrund bør du ik..
22 nov - 
Det er deres forskningscenter der flytter fra et sted i..

Company Announcement

Copenhagen, Denmark; October 5, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting the board decided to grant 6,019 restricted stock units and 18,756 warrants to employees of the company and two of the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,432.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,432. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 459.69.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody® and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 32

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
22 nov
GEN
Bliver stadig nød til at kommenterer på dine skriv TheNote:   Det er stadigvæk kun lidt over et år s..
15
22 nov
GEN
GW det er ikke smart at du åbner munden så meget når du griner , man kan jo se at der er helt tomt i..
13
22 nov
GEN
Note nu må du stoppe!Hvis du vil tages seriøs nytte det ikke noget du er så unyanceret, det er meget..
11
22 nov
GEN
"Jan W. har snorksovet i 2 år. Det får konsekvenser for Genmab og dermed aktionærerne. Og det er nær..
9
18 nov
GEN
Fantastisk konklusion 😂 Hvis nu professor Torben M Andersen en dag opretter en profil her på EI, og..
9
22 nov
GEN
Hvilke udfordringer. Genmab spytter den ene nyhed ud efter den anden og har de sidste 4 aar opjuster..
7
22 nov
GEN
Hvis du ikke synes om selskabet og ikke øjner værdi, så er det meget enkelt ikke at være med i aktie..
6
22 nov
GEN
Genmab er intet mindre end et fantastisk selskab.   EI´s absolut største orakel spår den i kurs 1.10..
5
20 nov
GEN
Jeg kan godt lide din nye smileyer. Det er et meget godt tegn på, hvor hårdt du prøver på at få en r..
5
17 nov
GEN
Mon ikke dette bliver en af de sjældne aftaler, hvor stort set hele milestone pakken ender med at bl..
5

Formuepleje køber igen teleaktier: Flere års nedtur giver muligheder

23-11-2017 15:32:39
Fra tidligere ikke at have villet røre teleaktier med en ildtang er Formuepleje vendt rundt og har nu flere selskaber i porteføljen.Teleselskaberne har gennem flere år været udfordret af hård konkurrence, lave priser og et tungt investeringsbehov, hvilket har gjort sektoren upopulær blandt investorerne på aktiemarkedet.På det seneste er den udvikling dog vendt, og de seneste to-tre uger har telese..

Vestas/HSBC: Lavere prisforudsætninger bag hug på 22 pct. i kursmålet

23-11-2017 13:34:01
Vindindustrien oplever markedsturbulens og prispres på vindmøller, hvilket har fået storbanken HSBC til at skære kraftigt i kursmålene for selskaber som Vestas, Siemens Gamesa og Nordex.- Prispresset er intensiveret og påvirker marginerne for alle vindmølleproducenter. Vi venter, at det negative momentum vil fortsætte, indtil der kommer tegn på en stabilisering af priserne under auktionssystemerne..

Aktier/middag: Vestas-nedtur for femte dag i træk tynger C20

23-11-2017 11:33:16
Der er en overvægt af røde aktier på det danske aktiemarked torsdag, hvor særligt Vestas og FLSmidth er ramt af udsalg, mens Royal Unibrew bliver belønnet for sit regnskab for tredje kvartal.Omkring 11.30-tiden falder det toneangivende C20 Cap-indeks 0,5 pct. til 1115,75. Aktiviteten er påvirket af, at de amerikanske børser holder lukket som følge af thanksgiving.For femte dag i træk dykker Vestas..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Torsdagens aktier: Vestas' november-nedtur fik et nyt kapitel - NY
2
Vestas i laveste niveau i over to år
3
Pandora: Amerikanere øger spekulation i kursfald
4
Fingerprint Cards: Rygter om kinesisk bud sætter skub i aktien
5
Vestas/HSBC: Lavere prisforudsætninger bag hug på 22 pct. i kursmålet

Relaterede aktiekurser

Genmab A/S 1.198,00 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
24. november 2017 05:02:59
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20171123.3 - EUROWEB7 - 2017-11-24 05:02:59 - 2017-11-24 05:02:59 - 1 - Website: OKAY